Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
· manilatimes.net
**media[1182053]**SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Company has been invited to participate in the Evercore 2nd China Biotech Summit, where it presented multiple key R&D highlights during a fireside chat. At the event, the Company presented updated clinical data for ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]). Regarding T-cell engager (TCE) technologies, beyond its previously disclosed proprietary AnTenGager® TCE platform, the Company showcased the TriGager™ TCE platform and multiple TCE functional modules for the first time. This further demonstrates the Company's complete TCE engineering technology toolbox and illustrates the technical principles behind the TriGager™ TCE platform. In addition, the Company also introduced ATG-207, a first-in-class αCD3-TGF-β bifunctional fusion protein.1. ATG-022（CLDN18.2 ADC）Latest data from the Phase II CLINCH study: As of June 26, 2026, among patients with moderate to high CLDN18.2 IHC 2+ ≥ 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 42.4% (14/33) and the disease control rate (DCR) was 90.9% (30/33), with a median overall survival (mOS) of 12.85 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the DCR was 86.7% (26/30), and the mOS was not yet reached, with a median follow-up of 14.03 months. One patient in each of the two dose groups achieved a complete response (CR).Favorable safety profile: Compared with the data cutoff of December 25, 2025, the incidence of Grade ≥3 treatment-related adverse events (TRAEs) in the 1.8 mg/kg dose cohort increased slightly from 19.4% to 21.0%, with only 9.7% of patients experiencing dose reduction due to TRAEs. These data demonstrate that despite more than six months of ongoing treatment follow-up and potential toxin accumulation in vivo, the incidence of Grade ≥3 TRAEs remained stable in the 1.8 mg/kg dose cohort. This favorable safety profile supports the combination of ATG-022 with chemotherapy and anti-PD-1 antibodies in the first-line setting, enabling the full therapeutic potential of ATG-022.mOS not yet reached in the 1.8mg/kg dose cohort: With a median follow-up of 14.03 months, mOS was not yet reached for the 1.8 mg/kg dose cohort, which further validates that ATG-022 can deliver durable long-term survival benefits for patients across all levels of CLDN18.2 expression.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase II CLINCH study, the Ib/II CLINCH-2 study, and the pivotal Phase III CLINCH-3 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with anti-PD-1 antibodies and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with anti-PD-1 antibodies; and third-line therapy as monotherapy. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment.2. AnTenGager® & TriGager™ TCE Platform
SHANGHAI and HONG KONG
Aug. 19, 2026
/PRNewswire/ -- Antengene Corporation Limited (, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech co...